TriCAR19.20.22 T Cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TriCAR19.20.22 T Cells, covering 2026-04-15 to 2026-04-15. Get the full timeline:
Most recent: Clinical Trial Update: Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia [Phase 1]